Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum

Inclusion Criteria: * Subject is willing and able to give informed consent. * Subject is willing and able to participate in the study as an outpatient and is willing to comply with study requirements. * Subject is 18 years of age or older. * Subject has a diagnosis of pyoderma gangrenosum that involves total area of 3 cm2 or greater and is of sufficient severity to warrant systemic agents. * If female of childbearing potential, subject will have a negative urine pregnancy test at Screening and Week 0. * If female, subject will be either post-menopausal for \> 1 year, surgically sterile (hysterectomy or bilateral tubal ligation), or practicing one form of birth control (abstinence, oral contraceptive, estrogen patch, implant contraception, injectable contraception, IUD, diaphragm, condom, sponge, spermicides, or vasectomy of partner). Female subjects will continue to use contraception for 6 months following the last injection. * Screening laboratory results are within the following parameters: * Hemoglobin \> 9 g/dL * White blood cells \> 3.0 x 10 to the 9th power/L, \<14.0 x 10 to the 9th power/L (unless on oral corticosteroids and no signs/symptoms of infection) * Neutrophils \> 1.5 x 10 to the 9th power/L * Platelets \> 100 x 10 to the 9th power/L * Lymphocytes \> 0.5 x 10 to the 9th power/L * Serum creatinine within 1.5 times the upper limit of normal range * AST and ALT within 2 times the upper limit of normal range * Subject has been on a stable dose of…